S&P 500 index data: S&P 500 Copyright ©
All data supplied by Morningstar Real-Time Data. U.S. intraday real-time exchange quotes are sourced from BATS when available. End-of-day quotes for Nasdaq, NYSE, and Amex securities will appear 15 minutes after close. Graph times are Eastern Standard. © Copyright Morningstar, Inc .
|Start Premium Trial||Register For Free|
|P||F||Fund Financial Data (13,000+ funds)|
|P||F||Stock Financial Data (7,000+ stocks)|
|P||F||Stock and Fund Screeners (basic)|
|P||F||Investing Articles and Market Commentary|
|P||F||Articles Archive (>30 days)|
|P||F||Discuss (dozens of stock, fund, bond, and general bulletin boards)|
|P||F||Portfolio Manager (basic)|
|P||F||Morningstar Investment Classroom|
|P||F||Access Your Portfolio Anytime, Anywhere via Your Mobile Device|
|P||Morningstar Fund Analyst Reports (full research on 1,700 funds, ETFs, and CEFs)|
|P||Morningstar Stock Analyst Reports (full research on more than 1,100 stocks)|
|P||Portfolio Manager (advanced with 10 X-Ray analyses, including recommendations)|
|P||Portfolio Monitor (monthly and on-demand personalized portfolio statements)|
|P||Morningstar Proprietary Stock Information (stock star ratings, buy/sell prices, economic moat ratings, and more)|
|P||Morningstar 5-Star Stock and Fund Favorites & Red Flags eNewsletters|
|P||Premium Stock and Fund Screeners (advanced with nearly infinite ways to find the best securities for you)|
|P||Discounts on Morningstar newsletters, books, seminars, and more|
Access these features and more when you sign up for Free Membership.
Join Morningstar today. It's Free.
Access these features and more when you sign up for Premium Membership.
Start your free 14-day trial today online
Your subscription may be tax deductible. Please contact your tax advisor.
|BG Medicine Welcomes Final Determination by CMS of 2014 Reimbursement for BGM Galectin-3(R) Test (2013/12/10)|
|BG Medicine Announces Preliminary Decision by CMS on Reconsideration of Reimbursement for BGM Galectin-3 Test (2013/9/30)|
|BG Medicine, Inc. Welcomes Galectin-3 Clinical Research Data From the PROTECT Study Conducted at Massachusetts General Hospital Demonstrating Predictive Value of Adverse Outcomes in Heart Failure Patients (2013/9/23)|
|BG Medicine to Announce Second Quarter 2013 Financial Results and Host Conference Call on Thursday, August 8, 2013 ()|
|BG Medicine, Inc. Announces Schedule of Events Related to Galectin-3 at the 17th Annual Scientific Meeting of the Heart Failure Society of America ()|
|BG Medicine, Inc. Prices $10.0 Million Public Offering of Common Stock (2014/4/3)|
|BG Medicine Announces Issuance of Patent Covering Galectin-3 Testing for Cardiac Resynchronization Therapy (2014/3/20)|
|BG Medicine Welcomes Inclusion of Galectin-3 in 2014 Indian Consensus Document on Cardiac Biomarkers (2014/3/10)|
|BG Medicine Welcomes La Jolla Pharmaceutical Company's Announcement of Positive Top-Line Results of Phase 2 Clinical Trial of Novel Pharmaceutical Compound Targeting Galectin-3 in Chronic Kidney Disease (2014/3/12)|
|BG Medicine Reports 2013 Fourth Quarter and Year End Financial Results (2014/3/20)|
Click above to view more mutual fund data and stats for bgmd - BG Medicine, Inc..